Abvc Biopharma Inc (ABVC)

$2.64 -0.22 (-7.70%)
Market Cap 50.95M
Revenue (ttm) 510,000.00
Net Income (ttm) -4.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -960.78%
Debt to Equity Ratio 0.00
Volume 233,355
Avg Vol 464,568
Day's Range N/A - N/A
Shares Out 16.98M
Stochastic %K 61%
Beta 0.27
Analysts Strong Buy
Price Target $20.20

Company Profile

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II cl...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 668 0881
Address:
44370 Old Warm Springs Boulevard, Fremont, United States
BigdollarMaker
BigdollarMaker Aug. 7 at 5:05 PM
$ABVC Turn around your going the
0 · Reply
BigdollarMaker
BigdollarMaker Aug. 6 at 9:16 PM
$ABVC We are worth more than what the share price shows!
0 · Reply
ProfitGainer
ProfitGainer Aug. 6 at 7:41 PM
$ABVC More good news. https://finance.yahoo.com/news/abvc-biopharma-gains-confidence-international-113000935.html
0 · Reply
BigdollarMaker
BigdollarMaker Aug. 5 at 3:28 PM
$ABVC No going back!!
0 · Reply
BigdollarMaker
BigdollarMaker Aug. 4 at 5:37 PM
$ABVC $BB $GORO Bring on that great news$$$$$
0 · Reply
ProfitGainer
ProfitGainer Aug. 4 at 4:46 PM
$ABVC Lots of good things coming.
0 · Reply
BigdollarMaker
BigdollarMaker Aug. 4 at 4:41 PM
$ABVC $BB $GORO We are having a good time$$
0 · Reply
SalmanAziz
SalmanAziz Aug. 2 at 2:32 PM
$ABVC how much to people think this stock will be worth by the end of 2025?
1 · Reply
PharmaExpert
PharmaExpert Aug. 1 at 6:37 PM
$AKBA, $FDMT, $CLLS, $CRDF, $ABVC 🔥🔥🔥🔥🔥
1 · Reply
ProfitGainer
ProfitGainer Aug. 1 at 6:31 PM
$ABVC 8 days ago they had $1,046 Million from license revenue and now today's news they have $1.396 Million. That's another $350K https://finance.yahoo.com/news/oncox-deepens-abvc-alliance-110000194.html
0 · Reply
Latest News on ABVC
ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners

Dec 11, 2024, 6:30 AM EST - 8 months ago

ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners

ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners

Oct 22, 2024, 8:45 AM EDT - 10 months ago

ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners

ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements

Aug 15, 2024, 7:30 AM EDT - 1 year ago

ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements

AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share

Apr 18, 2024, 9:25 AM EDT - 1 year ago

AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share

ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M

Apr 17, 2024, 9:00 AM EDT - 1 year ago

ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M

ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M

Apr 10, 2024, 8:30 AM EDT - 1 year ago

ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M

ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M

Mar 26, 2024, 8:30 AM EDT - 1 year ago

ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M

ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine

Mar 19, 2024, 8:30 AM EDT - 1 year ago

ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine

ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update

Mar 14, 2024, 9:30 AM EDT - 1 year ago

ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update

ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues

Feb 15, 2024, 8:30 AM EST - 1 year ago

ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues

ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)

Feb 12, 2024, 8:30 AM EST - 1 year ago

ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)

ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share

Feb 8, 2024, 9:17 AM EST - 1 year ago

ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share

ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees

Jan 3, 2024, 7:24 AM EST - 1 year ago

ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees

ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study

Dec 7, 2023, 8:30 AM EST - 1 year ago

ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study

ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market

Nov 21, 2023, 8:30 AM EST - 1 year ago

ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market

ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M

Nov 16, 2023, 10:05 AM EST - 1 year ago

ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M

ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results

Nov 15, 2023, 9:00 AM EST - 1 year ago

ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results

ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million

Oct 26, 2023, 8:30 AM EDT - 1 year ago

ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million

ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase IIb Clinical Study

Oct 17, 2023, 8:30 AM EDT - 1 year ago

ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase IIb Clinical Study

ABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD)

Oct 9, 2023, 8:30 AM EDT - 1 year ago

ABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD)

ABVC BioPharma Provides Updates on ADHD Phase IIb Clinical Study

Aug 23, 2023, 8:30 AM EDT - 2 years ago

ABVC BioPharma Provides Updates on ADHD Phase IIb Clinical Study

ABVC Executes Cooperation Agreement for Strategic Investments

Aug 17, 2023, 9:19 AM EDT - 2 years ago

ABVC Executes Cooperation Agreement for Strategic Investments

ABVC BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement

Aug 10, 2023, 8:30 AM EDT - 2 years ago

ABVC BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement

ABVC Corporate Update and CEO's Letter to Shareholders

Aug 7, 2023, 8:30 AM EDT - 2 years ago

ABVC Corporate Update and CEO's Letter to Shareholders

ABVC Announces the Approval of the Plan for GMP Production Facilities of Vitargus by Taiwan Science Park Administration

Aug 3, 2023, 9:20 AM EDT - 2 years ago

ABVC Announces the Approval of the Plan for GMP Production Facilities of Vitargus by Taiwan Science Park Administration

ABVC Signs a Term Sheet to Earn Licensing Fees of up to $20M and Royalties of 5-12% of Net Sales

Aug 1, 2023, 8:30 AM EDT - 2 years ago

ABVC Signs a Term Sheet to Earn Licensing Fees of up to $20M and Royalties of 5-12% of Net Sales

ABVC BioPharma Announces Closing on $1.75 Million Registered Direct Offering

Jul 31, 2023, 9:30 AM EDT - 2 years ago

ABVC BioPharma Announces Closing on $1.75 Million Registered Direct Offering

ABVC BioPharma Announces Pricing of $1.75 Million Registered Direct Offering

Jul 27, 2023, 9:22 AM EDT - 2 years ago

ABVC BioPharma Announces Pricing of $1.75 Million Registered Direct Offering

ABVC Signs Term Sheet to Acquire Real Estate Assets for Strategic Investments

Jul 26, 2023, 8:30 AM EDT - 2 years ago

ABVC Signs Term Sheet to Acquire Real Estate Assets for Strategic Investments

ABVC BioPharma Announces Reverse Stock Split

Jul 24, 2023, 12:30 PM EDT - 2 years ago

ABVC BioPharma Announces Reverse Stock Split

The New CEO of ABVC BioPharma Takes Steps to Help Improve Cash Efficiency

Jul 6, 2023, 8:30 AM EDT - 2 years ago

The New CEO of ABVC BioPharma Takes Steps to Help Improve Cash Efficiency

ABVC BioPharma, Inc. Announces New CEO as It Targets Further Growth

Jun 26, 2023, 8:30 AM EDT - 2 years ago

ABVC BioPharma, Inc. Announces New CEO as It Targets Further Growth

ABVC BioPharma Subsidiary BioKey Projects $1.0 Million Proceeds From Dietary Supplement Production

Jun 20, 2023, 8:30 AM EDT - 2 years ago

ABVC BioPharma Subsidiary BioKey Projects $1.0 Million Proceeds From Dietary Supplement Production

ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF

Jun 12, 2023, 8:30 AM EDT - 2 years ago

ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF

ABVC BioPharma Announces Collaboration With MerDury BioPharma for New Product Development and Commercialization

Jun 6, 2023, 8:30 AM EDT - 2 years ago

ABVC BioPharma Announces Collaboration With MerDury BioPharma for New Product Development and Commercialization

ABVC BioPharma Vitargus® Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia

May 22, 2023, 8:30 AM EDT - 2 years ago

ABVC BioPharma Vitargus® Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia

ABVC BioPharma Provides ABV-1601 Update on Phase I Site Initiation Visit Conducted at Cedars-Sinai Medical Center (CSMC)

Apr 10, 2023, 8:30 AM EDT - 2 years ago

ABVC BioPharma Provides ABV-1601 Update on Phase I Site Initiation Visit Conducted at Cedars-Sinai Medical Center (CSMC)

ABVC BioPharma Provides Vitargus Update on Phase II Site Initiation Visit Conducted at Ramathibodi Hospital in Thailand

Apr 6, 2023, 8:30 AM EDT - 2 years ago

ABVC BioPharma Provides Vitargus Update on Phase II Site Initiation Visit Conducted at Ramathibodi Hospital in Thailand

ABVC BioPharma Announces Fiscal Year 2022 Financial and Operational Results

Mar 31, 2023, 6:49 PM EDT - 2 years ago

ABVC BioPharma Announces Fiscal Year 2022 Financial and Operational Results

ABVC BioPharma Provides Vitargus® Update on Phase II Site Initiation Visit Conducted at Srinagarind Hospital in Thailand

Mar 20, 2023, 7:00 AM EDT - 2 years ago

ABVC BioPharma Provides Vitargus® Update on Phase II Site Initiation Visit Conducted at Srinagarind Hospital in Thailand

ABVC BioPharma Receives Registration Approval for Maitake Mushroom Dietary Supplement by the Taiwan Ministry of Health and Welfare

Mar 14, 2023, 7:00 AM EDT - 2 years ago

ABVC BioPharma Receives Registration Approval for Maitake Mushroom Dietary Supplement by the Taiwan Ministry of Health and Welfare

ABVC BioPharma Provides 2023 Pipeline Update

Feb 28, 2023, 8:30 AM EST - 2 years ago

ABVC BioPharma Provides 2023 Pipeline Update

ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials

Feb 23, 2023, 4:16 PM EST - 2 years ago

ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials

ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus®

Feb 21, 2023, 8:30 AM EST - 2 years ago

ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus®

ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference

Jan 19, 2023, 8:30 AM EST - 2 years ago

ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference

FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer

Jan 5, 2023, 8:30 AM EST - 2 years ago

FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer

ABVC BioPharma Provides Vitargus® Update - Phase II Vitargus® Study Protocol Received Thai FDA Approval

Nov 17, 2022, 8:30 AM EST - 2 years ago

ABVC BioPharma Provides Vitargus® Update - Phase II Vitargus® Study Protocol Received Thai FDA Approval

ABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results

Nov 14, 2022, 6:20 PM EST - 2 years ago

ABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results

ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD)

Nov 7, 2022, 8:30 AM EST - 2 years ago

ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD)

Cedars-Sinai Medical Center Joins Phase I Clinical Study of ABVC BioPharma's Medication for Treating Depression in Cancer Patients

Nov 2, 2022, 8:30 AM EDT - 3 years ago

Cedars-Sinai Medical Center Joins Phase I Clinical Study of ABVC BioPharma's Medication for Treating Depression in Cancer Patients

BigdollarMaker
BigdollarMaker Aug. 7 at 5:05 PM
$ABVC Turn around your going the
0 · Reply
BigdollarMaker
BigdollarMaker Aug. 6 at 9:16 PM
$ABVC We are worth more than what the share price shows!
0 · Reply
ProfitGainer
ProfitGainer Aug. 6 at 7:41 PM
$ABVC More good news. https://finance.yahoo.com/news/abvc-biopharma-gains-confidence-international-113000935.html
0 · Reply
BigdollarMaker
BigdollarMaker Aug. 5 at 3:28 PM
$ABVC No going back!!
0 · Reply
BigdollarMaker
BigdollarMaker Aug. 4 at 5:37 PM
$ABVC $BB $GORO Bring on that great news$$$$$
0 · Reply
ProfitGainer
ProfitGainer Aug. 4 at 4:46 PM
$ABVC Lots of good things coming.
0 · Reply
BigdollarMaker
BigdollarMaker Aug. 4 at 4:41 PM
$ABVC $BB $GORO We are having a good time$$
0 · Reply
SalmanAziz
SalmanAziz Aug. 2 at 2:32 PM
$ABVC how much to people think this stock will be worth by the end of 2025?
1 · Reply
PharmaExpert
PharmaExpert Aug. 1 at 6:37 PM
$AKBA, $FDMT, $CLLS, $CRDF, $ABVC 🔥🔥🔥🔥🔥
1 · Reply
ProfitGainer
ProfitGainer Aug. 1 at 6:31 PM
$ABVC 8 days ago they had $1,046 Million from license revenue and now today's news they have $1.396 Million. That's another $350K https://finance.yahoo.com/news/oncox-deepens-abvc-alliance-110000194.html
0 · Reply
BigdollarMaker
BigdollarMaker Aug. 1 at 4:33 PM
$ABVC Don't want to jinx us "but"
0 · Reply
BigdollarMaker
BigdollarMaker Jul. 31 at 5:01 PM
$ABVC We know it's just a matter of time before we fly,price dropping
0 · Reply
ProfitGainer
ProfitGainer Jul. 31 at 4:23 PM
$ABVC
0 · Reply
BigdollarMaker
BigdollarMaker Jul. 31 at 2:05 PM
$ABVC throw me a rope, so I can go back up!!
0 · Reply
BigdollarMaker
BigdollarMaker Jul. 30 at 7:41 PM
$ABVC We are trying not to fall, but just not holding up.:(
0 · Reply
ProfitGainer
ProfitGainer Jul. 28 at 11:23 PM
$ABVC
0 · Reply
BigdollarMaker
BigdollarMaker Jul. 28 at 3:41 PM
$ABVC Can't wait for news and we are all saying!$$$$
0 · Reply
BigdollarMaker
BigdollarMaker Jul. 25 at 5:05 PM
$ABVC Today ouch, but we could go from red to green. Fingers crossed!
0 · Reply
BigdollarMaker
BigdollarMaker Jul. 25 at 2:29 PM
$ABVC How long before we are compliant again?
1 · Reply
ProfitGainer
ProfitGainer Jul. 24 at 10:02 PM
$ABVC Another $100K payment today. https://finance.yahoo.com/news/abvc-biopharma-strengthens-oncology-partnership-130000204.html
0 · Reply
BigdollarMaker
BigdollarMaker Jul. 24 at 2:17 PM
$ABVC
0 · Reply
ProfitGainer
ProfitGainer Jul. 23 at 7:01 PM
$ABVC https://www.tipranks.com/news/the-fly/sixteen-new-option-listings-on-july-23rd-thefly
0 · Reply